Obesity causes insulin resistance by increasing activation of the sympathetic nervous system and the release of the stress hormone norepinephrine, according to a new study.
GLP-1 agonists – of which Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide) are the most ...
Diabetes is an epidemic across the nation – the CDC reports it affects over 37 million Americans – and what is true ...
FOX 32 Chicago on MSN3h
Experimental diabetes treatment helps Chicago woman go off insulinA Chicago woman who has struggled with Type 1 diabetes since childhood is now off insulin, thanks to doctors at the ...
Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and ...
"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...
GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...
Turmeric is a natural herb that may affect how well other medications and supplements work. This includes cancer medications ...
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
Cardinal Health plans to buy two companies that will expand its diabetes and gastroenterology businesses as part of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback